A PHASE 2 MULTICENTER STUDY OF CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WHO FAIL TO ACHIEVE RESPONSE WITH INJECTABLE AZACITIDINE OR DECITABINE

被引：0

作者：

Garcia-Manero, G. ^{[1
]}

Silverman, L. R. ^{[2
]}

Komrokji, R. S. ^{[3
]}

Mufti, G. J. ^{[4
]}

Seymour, J. F. ^{[5
]}

Tsai, K. ^{[6
]}

Reiser, D. ^{[7
]}

Skikne, B. S. ^{[7
]}

Beach, C. L. ^{[7
]}

Fenaux, P. ^{[8
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA

[3] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Malignant Hematol, Tampa, FL 33682 USA

[4] Kings Coll Hosp NHS Fdn Trust, Dept Haematol Med, London, England

[5] PeterMacCallum Canc Ctr, Dept Haematol, East Melbourne, Australia

[6] Celgene Corp, Dept Biostat, Summit, NJ USA

[7] Celgene Corp, Clin Dev, Summit, NJ USA

[8] Hop St Louis, Serv Hematol Seniors, Paris, France

来源：

关键词：

D O I：

10.1016/S0145-2126(15)30058-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S28 / S28

页数：1